Literature DB >> 9201955

2-Oxo-3-alkynoic acids, universal mechanism-based inactivators of thiamin diphosphate-dependent decarboxylases: synthesis and evidence for potent inactivation of the pyruvate dehydrogenase multienzyme complex.

A Brown1, N Nemeria, J Yi, D Zhang, W B Jordan, R S Machado, J R Guest, F Jordan.   

Abstract

A new class of compounds, the 2-oxo-3-alkynoic acids with a phenyl substituent at carbon 4 was reported by the authors as potent irreversible and mechanism-based inhibitors of the thiamin diphosphate- (ThDP-) dependent enzyme pyruvate decarboxylase [Chiu, C.-F., & Jordan, F. (1994) J. Org. Chem. 59, 5763-5766]. The method has been successfully extended to the synthesis of the 4-, 5-, and 7-carbon aliphatic members of this family of compounds. These three compounds were then tested on three ThDP-dependent pyruvate decarboxylases: the Escherichia coli pyruvate dehydrogenase multienzyme complex (PDHc) and its E1 (ThDP-dependent) component, pyruvate oxidase (POX, phosphorylating; from Lactobacillus plantarum),and pyruvate decarboxylase (PDC) from Saccharomycescerevisiae. All three enzymes were irreversibly inhibited by the new compounds. The 4-carbon acid is the best substrate-analog inactivator known to date for PDHc, more potent than either fluoropyruvate or bromopyruvate. The following conclusions were drawn from extensive studies with PDHc: (a) The kinetics of inactivation of PDH complexes and of resolved E1 by 2-oxo-3-alkynoic acids is time- and concentration-dependent. (b) The 4-carbon acid has a Ki 2 orders of magnitude stronger than the 5-carbon acid, clearly demonstrating the substrate specificity of PDHc. (c) The rate of inactivation of PDH complexes and of resolved E1 by 2-oxo-3-alkynoic acids is enhanced by the addition of ThDP and MgCl2. (d) Pyruvate completely protects E1 and partially protects PDHc from inactivation by 2-oxo-3-butynoic acid. (e) E1 but not E2-E3 is the target of inactivation by 2-oxo-3-butynoic acid. (f) Inactivation of E1 by 2-oxo-3-butynoic acid is accompanied by modification of 1.3 cysteines/E1 monomer. The order of reactivity with the 4-carbon acid was PDHc > POX > PDC. While the order of reactivity with PDHc and POX was 2-oxo-3-butynoic acid > 2-oxo-3-pentynoic acid > 2-oxo-3-heptynoic acid, the order of reactivity was reversed with PDC.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9201955     DOI: 10.1021/bi970094y

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  5 in total

1.  Thiamine supplementation attenuated hepatocellular carcinoma in the Atp7b mouse model of Wilson's disease.

Authors:  Christian T Sheline
Journal:  Anticancer Res       Date:  2011-10       Impact factor: 2.480

2.  Efficient coupling of catalysis and dynamics in the E1 component of Escherichia coli pyruvate dehydrogenase multienzyme complex.

Authors:  Sachin Kale; Gözde Ulas; Jaeyoung Song; Gary W Brudvig; William Furey; Frank Jordan
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-23       Impact factor: 11.205

3.  Thioacetamide-induced fulminant hepatic failure induces cerebral mitochondrial dysfunction by altering the electron transport chain complexes.

Authors:  Kiranmai Chadipiralla; Pallu Reddanna; Radhakrishna M Chinta; Pichili Vijaya Bhaskar Reddy
Journal:  Neurochem Res       Date:  2011-08-31       Impact factor: 3.996

4.  Acetylphosphinate is the most potent mechanism-based substrate-like inhibitor of both the human and Escherichia coli pyruvate dehydrogenase components of the pyruvate dehydrogenase complex.

Authors:  Natalia S Nemeria; Lioubov G Korotchkina; Sumit Chakraborty; Mulchand S Patel; Frank Jordan
Journal:  Bioorg Chem       Date:  2006-10-27       Impact factor: 5.275

5.  The effect of MEP pathway and other inhibitors on the intracellular localization of a plasma membrane-targeted, isoprenylable GFP reporter protein in tobacco BY-2 cells.

Authors:  Michael Hartmann; Andrea Hemmerlin; Elisabet Gas-Pascual; Esther Gerber; Denis Tritsch; Michel Rohmer; Thomas J Bach
Journal:  F1000Res       Date:  2013-08-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.